

February 10, 2020

**Otsuka Pharmaceutical Factory, Inc. introduces cogeneration system that contributes to CO<sub>2</sub> emission reductions and stable supplies of pharmaceuticals to its Toyama Factory**

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara), a subsidiary of Otsuka Holdings Co., Ltd., (Head Office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi) has introduced a cogeneration system\*<sup>1</sup> facility that contributes to reducing CO<sub>2</sub> emissions and stably supplying pharmaceuticals to its Toyama Factory (Imizu, Toyama, Japan). The completion ceremony was held on February 7.

The Toyama Factory's cogeneration system facility uses natural gas as fuel to generate power and uses the waste heat produced during the power generation to produce steam and hot water. With the introduction of the system, substantial improvements are expected in energy-use efficiencies, and the annual CO<sub>2</sub> emissions at Toyama Factory can be reduced by approximately 1,800 tons. This is equivalent to approximately 17% of the annual emissions of the Toyama Factory.

The Otsuka Group has identified climate change, resource circulation, and water conservation as CSR Materiality for developing environmental initiatives.

For climate change, with the goal of reducing CO<sub>2</sub> emissions by 30% by 2030,\*<sup>2</sup> the Group is actively engaged in reducing CO<sub>2</sub> emissions, including the introduction of CO<sub>2</sub>-free electricity as part of the efforts to achieve this goal.

This facility is also excellent for disaster resistance, such as earthquakes, and is a BCP\*<sup>3</sup> response facility that allows for continued production of

pharmaceuticals through the use of in-house power generation during blackouts. Toyama Factory manufactures IV solutions, the main products of Otsuka Pharmaceutical Factory, which are essential drugs in emergencies. In addition, it is the only factory in Japan to manufacture intravenous fat emulsions. As a leading company of IV solutions in Japan, we will continue to strive to provide a stable supply of products.



Completion ceremony held on February 7

The Otsuka Group is working to contribute to the health of people worldwide under the corporate philosophy of “Otsuka-people creating new products for better health worldwide.” In its efforts, each group company collaborates to optimize energy utilization and contributes to the realization of a low-carbon society and a sustainable society.

\*1 System that uses fuels such as natural gas, LP gas, etc. to generate power via engines, turbines, fuel cells, etc., while recovering the waste heat generated during the process. By doing so, heat and electricity can be used without being wasted.

\*2 From group company 2017 levels. Applies to CO<sub>2</sub> emissions both in Japan and overseas.

\*3 BCP (Business Continuity Plan)

## Company Profile

### Otsuka Pharmaceutical Factory, Inc.

Established : October 7, 1969 (founded September 1, 1921)  
Capital : 80 million yen  
Representative : Shinichi Ogasawara, President and Representative Director  
Head Office : 115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan  
Employees : 2,247 (as of December 31, 2019)  
Business Description : Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, functional foods, etc.  
URL : <https://www.otsukakj.jp/en/>

### Otsuka Holdings Co., Ltd.

Established : July 8, 2008  
Capital : 81.69 billion yen  
Representative : Tatsuo Higuchi, President and Representative Director, CEO  
Head Office : 2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo 101-0048, Japan  
Employees : 104 (as of December 31, 2019)  
Business Description : Holding company